Industry News
Xenotransplants: not quite around the corner
Pig hearts, kidneys and livers could be available for transplant into humans within five to seven years, according to the latest reports from the American Association for the Advancement of Science meeting currently underway in Boston. [ + ]
Acyte Biotech capitalises on tiny microbes
Two major multinational pharmaceutical companies and two ASX-listed biotechs are vying for the a new biopharmaceutical platform technology developed by Acyte Biotech, a spin-off company from the University of New South Wales. [ + ]
IBM recruits partners for life sciences push
IBM has rolled out a new set of initiatives directed at business partners in the life sciences. [ + ]
Stoush demonstrates need to discuss data sharing
Fresh from a clash between a marine biologist and a Massachusetts Institute of Technology (MIT) associate about sharing and publishing publicly-available research, a group of scientists is meeting this week at the US National Academy of Sciences to try to reach consensus on the issue. [ + ]
Queensland biotech's reclusive benefactor
Self-made billionaire and secretive philanthropist Charles Feeney appears to have a soft spot for Queensland's biotechnology sector. [ + ]
CSL looks to the US after solid half-year result
Blood products and vaccine manufacturer CSL has announced it more than doubled its interim profit to $57.5 million on the back of its acquisition of Swiss plasma supplier ZLB last year. [ + ]
US bioinformatics funding extends to small companies
The Biological Database and Informatics program (BD&I) at the US National Science Foundation is expanding the list of targets for $8 million in grants it is currently awarding. [ + ]
Cochlear bucks uncertainty, meets expectations
Cochlear shares gained $A3.90 (+10.1 per cent) to close at $A42.50 on February 18 after half-yearly reports for the six months ended 31 December 2001 showed that the company would meet its long-term growth target of 20 per cent a year. [ + ]
Ambri prepares its first instrument for market
Sydney-based nanotechnology company Ambri Limited is on track to deliver its first biosensor to the Australian market in June, after hooking up with local instrument manufacturer Vision Biosystems. [ + ]
'Post-genomic era' challenges instrument makers
Soft revenues recorded by life science instrument giant Applied Biosystems in the second quarter of its 2002 fiscal year sent a shockwave through the markets last month. [ + ]
Florigene gets the Tasmanian blues
Blue carnations won't be appearing in Tasmanian gardens, after a Melbourne molecular breeder vowed it "would not waste its time" trying to have a GMO ban in the state overturned. [ + ]
Spirits up at Amrad despite revenue slide
A promising development pipeline is keeping spirits high at Amrad Corporation despite its posting a $54.6 million drop in revenues in the last half of 2001. [ + ]
GE free? Don't tell us about it, says Qld govt
Voluntary bans by local farmers are a preferable way of creating GM crop-free areas than passing State laws, says Queensland Premier Peter Beattie. [ + ]
Interim loss, but EpiTan still in the sun
The Melbourne company behind a tanning drug has posted a $1.5 million interim loss as it pushes towards advanced human trials. [ + ]
Ciphergen teams up on AIDS research using protein chips
US company Ciphergen Biosystems has signed two joint development agreements that will call on its protein chips to find out why AIDS does not progress in a small percentage of HIV-infected individuals. [ + ]
